Temporal trends in cardiovascular mortality among patients with hematological malignancies: a 20-year perspective.

IF 2.1 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Expert Review of Cardiovascular Therapy Pub Date : 2025-01-01 Epub Date: 2025-02-12 DOI:10.1080/14779072.2025.2463332
Gemina Doolub, Avraham Raichman, Dmitry Abramov, Vijay Bang, Purvi Parwani, Kamaraj Karunanithi, Hussam Abdel-Qadir, Ofer Kobo, Mamas A Mamas
{"title":"Temporal trends in cardiovascular mortality among patients with hematological malignancies: a 20-year perspective.","authors":"Gemina Doolub, Avraham Raichman, Dmitry Abramov, Vijay Bang, Purvi Parwani, Kamaraj Karunanithi, Hussam Abdel-Qadir, Ofer Kobo, Mamas A Mamas","doi":"10.1080/14779072.2025.2463332","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>We present an analysis of cardiovascular-related deaths specific to hematological cancer patients in the United States from 1999 to 2020, examining trends in relation to age, gender, and type of hematological cancer.</p><p><strong>Research design and methods: </strong>Utilizing the Multiple Cause of Death databases, our research included 88,146 decedents with cardiovascular primary cause of death and with hematologic disease. We determined the percentage of cardiovascular deaths associated with each disease category. Furthermore, we developed age-adjusted mortality rates, categorizing them based on sex, age, race, Latino origin, and the type of hematological cancer.</p><p><strong>Results: </strong>Between 1999 and 2020, there was a decreasing temporal trend in overall cardiovascular mortality for lymphoma, leukemia and multiple myeloma (-38.8% -31.8% & -29.4%). The most common cardiovascular mortality cause in the hematological malignancy population was ischemic heart disease, followed by cerebrovascular disease (53.4%, 20.2%). African American, Asian, and White patients showed decreasing for overall CV death for all hematological malignancies, with African American subgroups showing the lowest mortality reduction over time (AAMR: -26.8%, -41.2%, -33.3%). However, hypertension mortality increased for most racial groups.</p><p><strong>Conclusions: </strong>Over the last 2 decades, the rate of cardiovascular mortality amongst patients with underlying hematological malignancy has decreased.</p>","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"35-43"},"PeriodicalIF":2.1000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Cardiovascular Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14779072.2025.2463332","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: We present an analysis of cardiovascular-related deaths specific to hematological cancer patients in the United States from 1999 to 2020, examining trends in relation to age, gender, and type of hematological cancer.

Research design and methods: Utilizing the Multiple Cause of Death databases, our research included 88,146 decedents with cardiovascular primary cause of death and with hematologic disease. We determined the percentage of cardiovascular deaths associated with each disease category. Furthermore, we developed age-adjusted mortality rates, categorizing them based on sex, age, race, Latino origin, and the type of hematological cancer.

Results: Between 1999 and 2020, there was a decreasing temporal trend in overall cardiovascular mortality for lymphoma, leukemia and multiple myeloma (-38.8% -31.8% & -29.4%). The most common cardiovascular mortality cause in the hematological malignancy population was ischemic heart disease, followed by cerebrovascular disease (53.4%, 20.2%). African American, Asian, and White patients showed decreasing for overall CV death for all hematological malignancies, with African American subgroups showing the lowest mortality reduction over time (AAMR: -26.8%, -41.2%, -33.3%). However, hypertension mortality increased for most racial groups.

Conclusions: Over the last 2 decades, the rate of cardiovascular mortality amongst patients with underlying hematological malignancy has decreased.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
恶性血液病患者心血管死亡率的时间趋势:20年的观察
背景:我们对1999年至2020年美国血液癌患者的心血管相关死亡进行了分析,研究了与年龄、性别和血液癌类型相关的趋势。研究设计和方法:利用多死因数据库,我们的研究纳入了88146例心血管主要死因和血液学疾病的死者。我们确定了与每种疾病类别相关的心血管死亡百分比。此外,我们制定了年龄调整死亡率,根据性别、年龄、种族、拉丁裔和血液学癌症类型对其进行分类。结果:1999 - 2020年,淋巴瘤、白血病和多发性骨髓瘤的心血管疾病总死亡率呈下降趋势,分别为-38.8%、-31.8%和-29.4%。血液恶性肿瘤人群中最常见的心血管疾病死亡原因是缺血性心脏病,其次是脑血管疾病(53.4%,20.2%)。非洲裔美国人、亚洲人和白人患者的所有血液学恶性肿瘤CV总死亡率均下降,其中非洲裔美国人亚组的死亡率随时间降低最低(AAMR: -26.8%, -41.2%, -33.3%)。然而,高血压死亡率在大多数种族群体中都有所上升。结论:在过去的20年里,潜在的血液恶性肿瘤患者的心血管死亡率已经下降。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Expert Review of Cardiovascular Therapy
Expert Review of Cardiovascular Therapy CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
3.70
自引率
0.00%
发文量
82
期刊介绍: Expert Review of Cardiovascular Therapy (ISSN 1477-9072) provides expert reviews on the clinical applications of new medicines, therapeutic agents and diagnostics in cardiovascular disease. Coverage includes drug therapy, heart disease, vascular disorders, hypertension, cholesterol in cardiovascular disease, heart disease, stroke, heart failure and cardiovascular surgery. The Expert Review format is unique. Each review provides a complete overview of current thinking in a key area of research or clinical practice.
期刊最新文献
Optimal treatment choices for adult atrial septal defects: the role of appropriate risk stratification. Association between pre-existing heart failure and in-hospital outcomes and management in admissions with cardiogenic shock. Mineralocorticoids and outcome improvement in heart failure patients with and without atrial fibrillation: a systematic review and a meta-analysis. Hormone deficiency and cardiovascular disease: clinical impact, treatment strategies and prognostic prediction. Beyond successful atrial fibrillation ablation: unmet patient needs, quality-of-life gap and patients' perspective.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1